This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Bioscience and genetic engineering company, Colossal, raised $60 million in a Series A funding round. Colossal is focused on developing new technologies and genetic tools to restore extinct species, and protect critically endangered species. One of the startup's long-term goals is to resurrect the woolly mammoth, and return it back to the arctic. Colossal also says it is developing technology that expands beyond animals, and has the potential to advance human health. Ben Lamm, co-founder and CEO of Colossal, joins Cheddar News' Closing Bell to discuss.
Residents were cleaning their homes Thursday after a 7.4-magnitude earthquake struck off the coast of Fukushima in northern Japan, smashing furniture, knocking out power and killing four people.
A New Zealand couple who believed they had dug up the world’s largest potato had their dreams turned to mash after Guinness World Records wrote to say that scientific testing had found it wasn’t, in fact, a potato after all.
Two years into the pandemic, many of us have regained a sense of normalcy. However, those in the healthcare industry are still confronting the virus every day, dealing with the physical, mental and psychological stress of the ongoing pandemic. Ben Mirtes, CFO of Ingenovis Health and Lydia Mobley, a travel nurse with Faststaff, who has spent the last two years going from hotspot to hotspot, joined Cheddar’s Opening Bell to reflect on their experiences in healthcare, and discuss why they are optimistic about a path forward.
Catching you up on what you Need to Know on March 16, 2022, with updates on Ukraine and Russia, a container ship gets stuck in the Chesapeake Bay, Disney employees stage a walkout over the "Don't Say Gay" law in Florida, and NASA completes its first spacewalk of 2022.
Food technology startup Tender Food raised $12 million in a seed round led by Chris Sacca's Lowercarbon Capital. Tender says it specializes in creating alternative meats with an authentic texture and is on a mission to make alternative meats so delicious, nutritious, and affordable, that eating meat from animals will no longer make sense. Christophe Chantre, co-founder & CEO of Tender Food, joins Cheddar News' Closing Bell to discuss.
Ryan Shearman, chief alchemist and co-founder at Aether, and Henry Elkus, founder of Helena, join Cheddar News to talk about the completion of an $18 million Series A funding round led by Helena.
As the Russia-Ukraine conflict continues to grow, so do concerns over the impact it could have on the international space community, and more specifically, the International Space Station. Those concerns come after Dmitry Rogozin, the director of Russia's state space agency, posted several tweets over the last few weeks in which he threatened to 'destroy Russia's cooperation on the ISS.' Olympia LePoint, rocket scientist and author of 'Answers Unleashed II: The Science of Attracting What You Want,' joined Cheddar News' Closing Bell to discuss.
